Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.61 |
| ▸ | CNR1 | P21554 | 1/20 | 0.61 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.61 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.61 |
| ▸ | GABRA3 | P34903 | 6/20 | 0.61 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.61 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.61 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.61 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.46 |
| ▸ | GABRP | O00591 | 1/20 | 0.46 |
| ▸ | GABRD | O14764 | 1/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.46 |
| ▸ | GABRE | P78334 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7721415 | 0.85 | GABRA1 (0.64) | PDE4DCNR1NTSR1OPRK1GABRA1 | |
| SCHEMBL13009749 | 0.85 | GABRA1 (0.66) | PDE4DCNR1NTSR1OPRK1GABRA1 | |
| SCHEMBL2843048 | 0.84 | ADRA1A (0.64) | PDE4DCNR1NTSR1OPRK1GABRA1 | |
| SCHEMBL11249580 | 0.83 | PDE4D (0.67) | PDE4DCNR1NTSR1OPRK1GABRA1 | |
| SCHEMBL26648747 | 0.83 | PDE4D (0.67) | PDE4DCNR1NTSR1OPRK1GABRA1 | |
| SCHEMBL7723209 | 0.82 | GABRA1 (0.64) | PDE4DCNR1NTSR1OPRK1GABRA1 | |
| SCHEMBL11821347 | 0.79 | CHRM1 (0.71) | PDE4DCNR1NTSR1OPRK1GABRA1 | |
| Ro-053061 SCHEMBL2615409 | 0.76 | PDE4D (0.71) | PDE4DCNR1NTSR1OPRK1GABRA1 | |
| Ro-053061 SCHEMBL2615407 | 0.76 | PDE4D (0.71) | PDE4DCNR1NTSR1OPRK1GABRA1 | |
| SCHEMBL1421181 | 0.76 | KMT2A (0.82) | PDE4DCNR1NTSR1OPRK1GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835424-B2 | Selective agents for pain suppression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835424-B2 | Selective agents for pain suppression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-20100317619-A1 | Selective Agents for Pain Suppression | COOK JAMES | 2010-12-16 | — | — | US | disclosed |
| US-20100261711-A1 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES | WISYS TECHNOLOGY FOUNDATION (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100130481-A1 | ANTICONVULSANT AND ANXIOLYTIC METHODS OF USING RECEPTOR SUBTYPE SELECTIVE AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-27 | — | — | US | disclosed |
| US-20100004226-A1 | STEREOSPECIFIC ANXIOLYTIC AND ANTICONVULSANT AGENTS WITH REDUCED MUSCLE-RELAXANT, SEDATIVE-HYPNOTIC AND ATAXIC EFFECTS | COOK JAMES M | 2010-01-07 | — | — | US | disclosed |
| US-7618958-B2 | Convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnosis; Ethyl 8-bromo-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20080108605-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20070299058-A1 | Anxiolytic Agents With Reduced Sedative And Ataxic Effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-7235656-B2 | Anxiolytic agents with reduced sedative and ataxic effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | GABRA3, GABRA2, GABRA1 | PDE4D 1042/4885CNR1 143/4885NTSR1 2864/4885 |
| US-20100317619-A1 | Selective Agents for Pain Suppression | CNR2, CNR1, OPRL1 | PDE4D 446/4885CNR1 2/4885NTSR1 588/4885 |
| US-20100130481-A1 | ANTICONVULSANT AND ANXIOLYTIC METHODS OF USING RECEPTOR SUBTYPE SELECTIVE AGENTS | GABRA3, GABRA2, GABRA1 | PDE4D 984/4885CNR1 41/4885NTSR1 346/4885 |
| US-20070299058-A1 | Anxiolytic Agents With Reduced Sedative And Ataxic Effects | GABRA3, GABRA2, GABRA1 | PDE4D 1042/4885CNR1 143/4885NTSR1 2864/4885 |
| US-20080108605-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | GABRA3, GABRA2, GABRA1 | PDE4D 1042/4885CNR1 143/4885NTSR1 2864/4885 |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | GABRA3, GABRA6, GABRA4 | PDE4D 1746/4885CNR1 113/4885NTSR1 1369/4885 |
| US-20100004226-A1 | STEREOSPECIFIC ANXIOLYTIC AND ANTICONVULSANT AGENTS WITH REDUCED MUSCLE-RELAXANT, SEDATIVE-HYPNOTIC AND ATAXIC EFFECTS | CHRNA6, GABRA6, CHRNA5 | PDE4D 605/4885CNR1 56/4885NTSR1 1557/4885 |
| US-20100261711-A1 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES | GABRA5, GABRA6, GABRA2 | PDE4D 371/4885CNR1 37/4885NTSR1 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.